The clinical data have shown that these antibodies targeting PD-1 and its ligand PD-L1 can block the activation of T cells and induce anti-tumor activities to improve patients' outcomes in the clinic. Nowadays, several small-molecules PD-1/PD-L1 drug-like inhibitors have been developed for the treatment of many cancers.